Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPsychiatry/Behavioral HealthSummaCare TMS Coverage Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentSummaCarePolicy N/A

    Transcranial Magnetic Stimulation for Major Depressive Disorder

    Customize your policy alerts

    Sign up for all summacare policy alerts

    Know when summacare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and medical-necessity requirements for TMS/rTMS, including initial treatment and retreatment, for commercial and Medicare members, with requirements for treatment-resistant major depressive disorder, provider supervision, contraindications, treatment limits, and covered or non-covered procedure codes.

    Policy Summary
    PayerSummaCare
    PolicyTranscranial Magnetic Stimulation for Major Depressive Disorder
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 8, 2026
    Last ReviewOct 8, 2026
    Next Review DateN/A
    Key ActionSubmit TMS requests for medical-necessity review with documentation of the MDD diagnosis, treatment history, psychotherapy trial, and qualified psychiatrist supervision.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    15+

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Minimum commercial authorization age
    30 sessionsMaximum commercial initial course
    4+ trialsCommercial adult medication trials
    50% reductionMedicare resistance threshold
    3Covered CPT codes
    12Not-covered procedure codes

    Medical Necessity and Coverage Criteria

    Commercial initial TMS

    Commercial initial TMS is medically necessary when all applicable criteria are met.

    Commercial initial treatment

    • Medication treatment failure or intolerance: Adult member failed 4 or more antidepressant medication trials from 2 separate classes; or an adolescent age 15-17 failed 2 antidepressant medication trials.Adults: >=4 trials from 2 classes; ages 15-17: 2 trials

      A failed trial requires an adequate therapeutic dose for at least 6 weeks without significant reduction in depressive symptoms, or documented intolerance or medical contraindication.

    • Psychotherapy and treatment delivery: An adequate evidence-based psychotherapy trial effective for MDD was completed without significant improvement in depressive symptoms; the device is FDA-cleared and used according to FDA labeling; and treatment consists of no more than 30 sessions.Maximum 30 sessions

    Commercial retreatment

    Commercial retreatment is medically necessary when all criteria are met.

    Commercial TMS retreatment: The member meets initiation criteria, has relapsed following TMS despite other treatment, and previously achieved at least a 50% reduction in depressive symptoms with TMS.Prior TMS response >=50% reduction

    Retreatment is for depression relapse after prior TMS benefit.

    Medicare initial left prefrontal rTMS

    Medicare initial left prefrontal rTMS is reasonable and necessary when all four primary criteria are met.

    Medicare initial treatment

    • Pharmacologic resistance, intolerance, or qualifying history: The member has no clinically significant response to two psychopharmacologic trials in the current episode from at least two classes, with at least one adequate mono- or poly-drug course; or cannot tolerate four trials from at least two classes with distinct side effects; or has a prior response to rTMS in a previous depressive episode; or is receiving ECT and rTMS is considered as a less invasive option.Resistance: <50% symptom reduction after >=6 weeks at FDA-recommended adult dose

      Objective measures such as PHQ-9 and/or HAM-D may document response.

    Medicare delivery requirements

    Medicare treatment must also satisfy general delivery requirements.

    Qualified delivery and setting: TMS is furnished according to accepted standards of medical practice, in a setting appropriate to the patient's medical needs and condition, without exceeding medical need, and by qualified personnel under the direct supervision of an experienced psychiatrist.Direct psychiatrist supervision

    The psychiatrist must be present in the area and immediately available but need not personally provide the treatment.

    Coverage is limited for members with seizure disorder or any seizure history, acute or chronic psychotic symptoms or disorders, specified neurological conditions, or prohibited implanted stimulators or magnetic-sensitive, conductive, or ferromagnetic metal within 30 cm of the TMS coil. Additional concerns include substance abuse at referral or treatment initiation, severe dementia, and known nonadherence with prior depression treatment. Dental amalgam fillings are acceptable.

    Evidence is insufficient for TMS used for conditions other than major depressive disorder and for nonstandard approaches, including accelerated TMS, low-field magnetic stimulation, and synchronized TMS. Secondary review is recommended for maintenance TMS, more than one repeat course, a repeat course after little or no initial improvement, or extending an initial or repeat course beyond the policy criteria.

    TMS must be ordered by and furnished under the direct supervision of an experienced psychiatrist. Treatment must be provided by qualified personnel, in an appropriate setting, according to accepted standards of medical practice, and in a manner that meets but does not exceed the member’s medical needs. Services that do not meet the psychiatrist ordering and supervision requirement are not medically reasonable and necessary and are not subject to coverage.

    Current evidence does not support TMS for major depression with psychotic features, including treatment-resistant or treatment-intolerant psychotic depression. The policy notes that large, controlled trials of TMS for psychotic depression have not been conducted.

    Covered and Non-Covered Codes

    CPT CodesCPTCovered
    90867Therapeutic repetitive transcranial magnetic stimulation treatment; planning
    90868Delivery and management, per session
    90869Subsequent motor threshold re-hyphendetermination with delivery and management
    CPT codes NOT coveredCPTNot Covered
    0858TExternally applied transcranial magnetic stimulation with concomitant measurement of evoked cortical potentials with automated report
    0889TPersonalized target development for accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation derived from a structural and resting-state functional MRI, including data preparation and transmission, generation of the target, motor threshold-starting location, neuronavigation files and target report, review and interpretation
    0890TAccelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including target assessment, initial motor threshold determination, neuronavigation, delivery and management, initial treatment day
    0891TAccelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including neuronavigation, delivery and management, subsequent treatment day
    0892TAccelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including neuronavigation, delivery and management, subsequent motor threshold redetermination with delivery and management, per treatment day
    95700-95726Electroencephalogram (EEG)
    95812Electroencephalogram (EEG) extended monitoring; 41-60 minutes
    9581361-119 minutes
    95816Electroencephalogram (EEG); including recording awake and drowsy
    95819Including recording awake and asleep
    1–10 of 12
    1/2
    Commercial Initial Treatment Course
    Maximum initial-treatment course30 sessions
    Applies toCommercial members receiving initial TMS treatment
    Treatment requirementThe course must not exceed the maximum of 30 sessions
    Typical TMS Course
    Session frequency1 session per day, 5 days per week
    Typical course duration6 weeks
    Session length

    Authorization, Documentation, and Safety Requirements

    Prior Authorization

    Prior Authorization and Coverage Review

    Obtain prior authorization and submit the applicable clinical documentation for commercial or Medicare coverage review before initiating TMS. Commercial determinations follow SummaCare criteria; Medicare determinations follow CMS/CGS LCD L36469 and applicable CMS guidelines, Hayes research, and industry standards.

    • Confirm that the requested treatment meets the applicable member-specific medical-necessity criteria.
    • Include diagnosis, treatment history, symptom measures, psychotherapy history, ordering-provider qualifications, safety screening, device information, and planned course.
    Step Therapy

    Commercial Antidepressant Trials

    For commercial members, document the required antidepressant treatment failures before requesting TMS for major depressive disorder.

    • Member must be age 15 or older and have confirmed major depressive disorder without psychosis.

    Treatment Overview

    Transcranial magnetic stimulation (TMS) is a noninvasive outpatient treatment that uses an electromagnetic coil to deliver pulsed magnetic energy and induce low-level electrical currents in targeted cortical tissue. Conventional protocols include high-frequency stimulation of the left dorsolateral prefrontal cortex and low-frequency stimulation of the right dorsolateral prefrontal cortex. A typical course is delivered once daily on weekdays for approximately six weeks, with sessions lasting about 40 minutes.

    Terminology

    HFL-TMS
    DefinitionHigh-frequency left repetitive transcranial magnetic stimulation
    Target siteLeft dorsolateral prefrontal cortex (DLPFC)
    Typical stimulation frequencyAbove 5 Hz and up to 10 Hz
    LFR-TMS
    DefinitionLow-frequency right repetitive transcranial magnetic stimulation
    Target siteRight dorsolateral prefrontal cortex (DLPFC)
    Typical stimulation frequencyBelow 1 Hz

    Transcranial Magnetic Stimulation

    Transcranial magnetic stimulation (TMS/rTMS)

    Coverage is limited to medically necessary TMS for treatment-resistant major depressive disorder under the applicable commercial or Medicare criteria.

    TMS for treatment-resistant MDD: TMS/rTMS is covered when the member meets the applicable commercial or Medicare MDD criteria, including medication resistance or intolerance, an adequate psychotherapy trial without significant improvement, qualified psychiatrist ordering, and direct supervision.Commercial age >=15; Medicare severe MDD criteria

    For commercial authorization, an FDA-cleared device and FDA-labeled use are required.

    Treatment Session Limits

    Commercial TMS Sessions
    Commercial initial-treatment limit30 TMS sessions maximum
    Applicable treatmentInitial commercial TMS treatment
    Coverage conditionThe treatment course must not exceed 30 sessions
    TMS Sessions
    Additional-session allowanceUp to 36 additional sessions
    PurposeExtend an acute course of care
    Typical schedule1 session per day, 5 days per week, for 6 weeks
    Policy Summary
    PayerSummaCare
    PolicyTranscranial Magnetic Stimulation for Major Depressive Disorder
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 8, 2026
    Last ReviewOct 8, 2026
    Next Review DateN/A
    Key ActionSubmit TMS requests for medical-necessity review with documentation of the MDD diagnosis, treatment history, psychotherapy trial, and qualified psychiatrist supervision.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCovered and Non-Covered CodesAuthorization, Documentation, and Safety RequirementsTreatment OverviewTerminologyTranscranial Magnetic StimulationTreatment Session Limits
    Approximately 40 minutes per session
    Additional sessionsUp to 36 additional sessions may extend an acute course to 6 weeks
    Medicare Pharmacologic Resistance
    Required symptom responseFailure to achieve a 50% reduction in depressive symptoms
    Medication-trial durationAt least 6 weeks
    Medication doseRecommended adult dose according to the FDA label
    Objective measuresPHQ-9 and/or HAM-D may be used to measure depressive symptoms
  1. Adults generally require failure of at least four antidepressant trials from two separate antidepressant classes.
  2. For adolescents ages 15–17, document failure of two antidepressant trials.
  3. A failed trial requires an adequate therapeutic dose for at least six weeks without significant reduction in depressive symptoms, or documented intolerance or medical contraindication.
  4. Step Therapy

    Medicare Pharmacologic Resistance or Intolerance

    For Medicare initial treatment, document pharmacologic resistance or intolerance in the current depressive episode, or an applicable prior-response or ECT circumstance.

    • Resistance requires lack of a clinically significant response, defined as failure to achieve a 50% reduction in depressive symptoms, after two psychopharmacologic trials from at least two different agent classes; at least one trial must be an adequate mono- or poly-drug course.
    • Each resistance trial must use the recommended adult dose under the FDA label for at least six weeks.
    • Alternatively, document inability to tolerate psychopharmacologic agents through four trials from at least two classes with distinct, intolerable side effects that are not expected to diminish or resolve with continued administration.
    • Medicare criteria may also be met by a history of response to rTMS in a previous depressive episode or, when the patient is receiving ECT, consideration of rTMS as a less invasive option.

    Unsupported block type: documentation

    Documentation Required

    Treatment History and Symptom Documentation

    The record must establish the covered diagnosis and show the complete treatment and symptom history supporting medical necessity.

    • Document confirmed severe or otherwise qualifying major depressive disorder, single or recurrent episode, and absence of psychosis where required.
    • Record all relevant antidepressant or psychopharmacologic agents, doses, durations, response, adverse effects, intolerance, and contraindications.
    • Document psychotherapy adequacy and outcome, including standardized symptom scores such as PHQ-9 or HAM-D when applicable.
    • For retreatment, document relapse after prior TMS despite other treatment and at least a 50% prior reduction in depressive symptoms with TMS.
    Documentation Required

    Qualified Psychiatrist Order

    The treatment order must be written by a qualified psychiatrist who has examined the patient, reviewed the medical record, and has experience administering TMS.

    • The ordering psychiatrist must be an MD or DO.
    • Document the examination, record review, treatment rationale, and the psychiatrist’s TMS experience.
    Documentation Required

    Device, Labeling, and Treatment Plan

    Use a U.S. Food and Drug Administration-cleared TMS device for an FDA-labeled indication and document the planned treatment course.

    • For commercial treatment, limit the course to a maximum of 30 sessions.
    • Do not use a device or treatment pattern outside its FDA-cleared labeling without applicable review and support.
    • Ensure the treatment plan identifies the indication, modality, course, and supervision arrangements.
    Denial Risk

    Safety and Contraindication Screening

    Before treatment, complete and document safety screening for seizure risk, psychosis, neurological disease, implanted devices or metal, substance use, dementia, and treatment adherence.

    • Screen for seizure disorder or any seizure history, except isolated febrile seizures in infancy without recurrence or subsequent treatment and seizures induced by ECT.
    • Assess for acute or chronic psychotic symptoms or disorders, neurological disease, severe dementia, and substance abuse at referral or treatment start.
    • Identify implanted magnetic-sensitive devices or conductive, ferromagnetic, or other magnetic-sensitive metal in the head or neck within 30 cm of the coil, including cochlear implants, ICDs, pacemakers, VNS devices, aneurysm clips or coils, staples, and stents. Dental fillings are acceptable.
    • Screen for VNS leads in the carotid sheath, other electrically or magnetically controlled implanted stimulators, and known nonadherence with prior depression treatment.
    Denial Risk

    Psychiatrist Supervision Required

    TMS must be furnished under the direct supervision of the ordering psychiatrist, with the physician present in the area and immediately available even if the physician does not personally administer every treatment.

    • The psychiatrist must have experience administering TMS.
    • Treatment not ordered by and furnished under a psychiatrist’s direct supervision is not medically reasonable and necessary and is not subject to coverage.
    Denial Risk

    Contraindications and High-Risk Conditions

    Do not proceed without appropriate review when contraindications or high-risk conditions are present; these conditions may require denial or secondary review.

    • Deny or escalate cases involving seizure disorder or seizure history, acute or chronic psychotic disorder, severe dementia, substance abuse at referral or treatment start, or nonadherence with prior depression treatment.
    • Do not treat when prohibited implanted stimulators or magnetic-sensitive or conductive metal are within 30 cm of the coil, including relevant head or neck implants; dental fillings are excluded.
    • Psychotic depression is not supported by current evidence, including treatment-resistant or treatment-intolerant psychotic depression.
    Denial Risk

    Unsupported Indications and Treatment Patterns

    Coverage is not supported for indications, modalities, or treatment patterns outside the qualifying MDD criteria; obtain secondary review when the source criteria identify insufficient evidence.

    • Unsupported or review-recommended uses include conditions other than major depressive disorder, including treatment of patients younger than 18 years of age.
    • Escalate a repeat course when the initial course produced little or no improvement, more than one repeat course, or continuation beyond the identified course limits.
    • Maintenance TMS and accelerated TMS, including twice-daily treatment, are not supported under the stated criteria.
    • Low-field magnetic stimulation, synchronized TMS, and other nonstandard TMS modalities are not supported.
    Denial Risk

    Failure to Meet Medical-Necessity Criteria

    Coverage may be denied when the applicable commercial or Medicare medical-necessity criteria are not met or when required supervision, documentation, or safety conditions are absent.

    • Commercial denial conditions include failure to document the qualifying MDD diagnosis, required antidepressant trials, adequate psychotherapy trial, FDA-cleared labeled use, or the maximum 30-session course.
    • Medicare denial conditions include failure to document qualifying severe MDD, pharmacologic resistance or intolerance or another permitted pathway, adequate psychotherapy with symptom measures, or a psychiatrist’s qualifying order and direct supervision.
    • Do not bill or initiate treatment when contraindications, unsupported indications, or non-covered treatment patterns remain unresolved.
    Failed Antidepressant Trial
    Clinical failureNo significant reduction in depressive symptoms after an antidepressant is taken at an adequate therapeutic dose for at least six weeks
    IntoleranceDocumented intolerance to the antidepressant medication
    Medical contraindicationA documented medical contraindication to the antidepressant medication